Categories
Change Password!
Reset Password!
A study was performed to determine if H. pylori therapy, excess weight of the body, and other anthropometric estimations are linked with incident erosive esophagitis, as a secondary aim of a study (HEROES trial) that evaluated the effectiveness of H. pylori therapy on functional dyspepsia symptoms.
Elevated waist circumference and excess body weight,
but not Helicobacter pylori (H. pylori) therapy forecast novel onset erosive esophagitis.
A study was
performed to determine if H. pylori therapy, excess weight of the
body, and other anthropometric estimations are linked with incident erosive
esophagitis, as a secondary aim of a study (HEROES trial) that evaluated the
effectiveness of H. pylori therapy on functional dyspepsia symptoms.
In H. pylori-positive subjects having
functional dyspepsia, the upper gastrointestinal endoscopy and anthropometric
evaluations were carried out at baseline and after 12 months. The enrolled
participants had no baseline reflux symptoms or esophagitis. Participants were
randomly allocated to either antibiotic
group (omeprazole, amoxicillin, and clarithromycin; n = 201) or control group
(omeprazole plus placebo; n = 203). The occurrence of esophagitis 12 months
after randomization, based on the therapy groups, and the link of body mass
index and other anthropometric estimations were the major endpoint.
The study incorporated 404 patients (mean age, 46.1 years). The 12-month follow-up endoscopic esophagitis rates for the control and antibiotic arms were 9.4% (19/203) and 10.9% (22/201) respectively. The number required to impair was 67. Baseline anthropometric estimations were carried out in 94% (380/404) of individuals.
The rates for subjects with and without elevated baseline waist circumference were 15.4% (24/156) and 6.7% (15/224), respectively. For normal body weight and overweight subjects, the 12-month follow-up esophagitis rates were found to be 6.0% (10/167) and 13.6% (29/213) respectively. After logistic regression, only the combination of elevated waist and higher body mass index and, but not H. pylori therapy was independently linked with novel-onset esophagitis (Odds ratio 2.88).
H. pylori
infection is not a major risk factor for developing reflux esophagitis in a
population of individuals having functional dyspepsia. However, increased body mass index, associated
with a concomitant increase in waist circumference (combined risk factors for
GERD), is considerably related to the development of erosive esophagitis.
Physicians should not be
excessively concerned about the risk of developing erosive esophagitis in H.
pylori-positive functional dyspepsia patients offered eradication
treatment.
International Journal of Obesity
Potential roles of Helicobacter pylori treatment, body mass index and waist circumference in the causation of erosive esophagitis: a randomized clinical trial (HEROES-GERD)
Felipe Mazzoleni et al.
Comments (0)